Real World Effectiveness, Safety and Pharmacokinetics of Switching Intravenous Vedolizumab Maintenance treatment to Subcutaneous Vedolizumab Therapy for Inflammatory Bowel Disease

被引：0
|
作者：
Volkers, A. [1 ]
Straatmijer, T. [1 ]
Duijvestein, M. [2 ]
Sales, A. [1 ]
Levran, A. [1 ]
van Schaik, F. [3 ]
Jeroen, M. [4 ]
Gecse, K. [1 ]
Ponsioen, C. [1 ]
Grootjans, J. [1 ]
Hanzel, J. [1 ]
Tack, G. [5 ]
Jansen, J. [6 ]
Hoentjen, F. [7 ]
de Boer, N. [1 ]
van der Marel, S. [8 ]
Dijkstra, G. [9 ]
Oldenburg, B. [3 ]
Lowenberg, M. [1 ]
van der Meulen, A. [4 ]
D'Haens, G. [1 ]
机构：
[1] Amsterdam UMC, Locat AMC, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Gastroenterol & Hepatol, Nijmegen, Netherlands
[3] Univ Med Ctr Utrecht, Dept Gastroenterol & Hepatol, Utrecht, Netherlands
[4] Leiden Univ, Med Ctr, Dept Gastroenterol & Hepatol, Leiden, Netherlands
[5] Med Ctr Leeuwarden, Dept Gastroenterol & Hepatol, Leeuwarden, Netherlands
[6] Onze Lieve Vrouw Hosp, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands
[7] Univ Alberta, Dept Med, Div Gastroenterol, Edmonton, AB, Canada
[8] Haaglanden Med Ctr, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands
[9] Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, Groningen, Netherlands
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP63
引用
收藏
页码：I108 / I109
页数：3
相关论文
共 50 条
  • [41] Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease
    Stefan Schreiber
    Axel Dignass
    Laurent Peyrin-Biroulet
    Greg Hather
    Dirk Demuth
    Mahmoud Mosli
    Rebecca Curtis
    Javaria Mona Khalid
    Edward Vincent Loftus
    Journal of Gastroenterology, 2018, 53 : 1048 - 1064
  • [42] REAL-WORLD SAFETY AND EFFICACY OF USTEKINUMAB AND VEDOLIZUMAB IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Hsu, Diane
    Lee, Justin
    Kotzen, Alison Borrman
    Bensen, Rachel
    Goyal, Alka
    GASTROENTEROLOGY, 2024, 166 (05) : S1210 - S1211
  • [43] REAL-WORLD SAFETY AND EFFICACY OF USTEKINUMAB AND VEDOLIZUMAB IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Hsu, Diane
    Lee, Justin
    Kotzen, Alison
    Bensen, Rachel
    Goyal, Alka
    GASTROENTEROLOGY, 2024, 166 (03) : S101 - S102
  • [44] REAL-WORLD SAFETY AND EFFICACY OF USTEKINUMAB AND VEDOLIZUMAB IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Hsu, Diane
    Lee, Justin
    Kotzen, Alison
    Bensen, Rachel
    Goyal, Alka
    INFLAMMATORY BOWEL DISEASES, 2024, 30 : S73 - S74
  • [45] REAL-WORLD SAFETY AND EFFICACY OF USTEKINUMAB AND VEDOLIZUMAB IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Anjur, Kavya
    Neiman, Nicole
    Kotzen, Alison
    Pond, Stephen
    Goyal, Alka
    GASTROENTEROLOGY, 2022, 162 (07) : S826 - S826
  • [46] Real-world evidence on effectiveness and safety of vedolizumab therapy for inflammatory bowel disease in Taiwan: Results from the TSIBD registry (VIOLET Study)
    Wei, S. C.
    Lin, W. C.
    Chang, C. H.
    Tu, C. H.
    Feng, I. C.
    Shieh, M. J.
    Chung, C. S.
    Yen, H. H.
    Chou, J. W.
    Tai, W. C.
    Wong, J. M.
    Liu, Y. H.
    Huang, T. Y.
    Chuang, C. H.
    Tsai, T. J.
    Chiang, F. F.
    Lu, C. Y.
    Hsu, W. H.
    Yu, F. J.
    Chao, T. H.
    Wu, D. C.
    Ho, A. S.
    Lin, H. H.
    Feng, C. L.
    Wu, K. L.
    Wong, M. W.
    Tung, C. C.
    Lin, C. C.
    Chen, C. C.
    Hu, H. M.
    Lu, L. S.
    Wang, H. S.
    Wu, I. C.
    Kuo, H. Y.
    Wu, J. F.
    Shih, H. Y.
    Ni, Y. H.
    Tang, S. L.
    Chang, H. C.
    Chen, P. H.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S428 - S430
  • [47] Clinical and biomarker remission is maintained after switch from monthly dosed intravenous to subcutaneous maintenance treatment with vedolizumab in Inflammatory Bowel Disease
    Pintar, S.
    Hanzel, J.
    Smrekar, N.
    Kozelj, M.
    Drobne, D.
    Kurent, T.
    Stabuc, B.
    Novak, G.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 834 - 834
  • [48] Switching from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease in clinical remission: a multicenter study from GETECCU
    Gros, B.
    Mancenido Marcos, N.
    Guardiola, J.
    Alonso Abreu, I.
    Rodriguez Lago, I.
    Alvarado, R.
    Ponferrada, A.
    Orobitg Bernades, J.
    Arguelles-Arias, F.
    Mesonero, F.
    Guerra, I.
    Canete, F.
    Madero, L.
    Borras, P.
    Rodriguez, G. E.
    Iborra, M.
    Castro, J.
    Caballero Mateos, A.
    Barreiro-de Acosta, M.
    Huguet Malaves, J. M.
    Brunet-Mas, E.
    Lopez Romero-Salazar, F.
    Caballol, B.
    Zabana, Y.
    Suria Bolufer, C.
    Soto, P.
    Castro, B.
    Marin, S.
    Porto-Silva, S.
    Benitez, J. M.
    Gutierrez, A.
    Iglesias-Flores, E.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1784 - I1786
  • [49] Irish data on the safety and efficacy of vedolizumab in the treatment of inflammatory bowel disease
    Judge, Ciaran
    McGettigan, Neasa
    Ryan, Timothy
    Hazel, Karl
    Singh, Pamla
    Parihar, Vikrant
    Stack, Roisin
    O'Connor, Anthony
    Dunne, Cara
    Cullen, Garret
    Egan, Laurence
    Harewood, Gavin
    MacCarthy, Finbar
    McKiernan, Susan
    Mulcahy, Hugh
    Murray, Frank
    Patchett, Stephen
    Sheridan, Juliette
    Cheriyan, Danny
    Farrell, Richard
    Keohane, John
    Kelly, Orlaith
    McNamara, Deirdre
    Ryan, Barbara
    O'Morain, Colm
    Sengupta, Subhasish
    O'Toole, Aoibhlinn
    Buckley, Martin
    McCarthy, Jane
    Doherty, Glen
    Kevans, David
    Slattery, Eoin
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2020, 55 (07) : 786 - 794
  • [50] A Retrospective United Kingdom Chart Review of Early Vedolizumab Experience: Real-World Treatment, Effectiveness and Safety in Inflammatory Bowel Disease (REVIVE)
    Cummings, Fraser
    Gaya, Daniel
    Irving, Peter
    Subramanian, Sreedhar
    Glen, Fiona
    Frere-Scott, Lucinda
    Demuth, Dirk
    Rathmell, Anna
    Owen, Glynn
    INFLAMMATORY BOWEL DISEASES, 2017, 23 : S25 - S26
12345